Key Highlights

  • Seres Therapeutics pivoted to a Q2 net profit of $4.6 million from a prior $19.9 million deficit.
  • The swing was primarily fueled by a $25 million gain tied to VOWST and reduced overhead.
  • SER-155 early data revealed an 80% clinical response rate without immunosuppressives by day 15.
  • Liquid assets and pending Nestlé payments are projected to sustain the runway into March 1, 2027.

Seres Therapeutics, Inc. (NASDAQ: MCRB) pivoted to a Q2 net profit of $4.6 million from a prior $19.9 million deficit, primarily fueled by a $25 million gain tied to VOWST and reduced overhead.

What Happened

Notably, SER-155 early data revealed an 80% clinical response rate without immunosuppressives by day 15, with Liquid assets and pending Nestlé payments projected to sustain the runway into March 1, 2027.

Market Reaction

The disclosed information does not include stock price or trading data for Seres Therapeutics following the Q2 results.

Outlook

Continued follow-up on SER-155's early clinical response data, alongside the timing of pending Nestlé payments supporting the runway into March 1, 2027, represent the next relevant developments for Seres Therapeutics.